Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit

British Journal of Clinical Pharmacology

Volumn 68, Issue 2, 2009, Pages 174-180

  Corrigan, Brian ^a   Feltner, Douglas E ^a   Ouellet, Daniele ^b   Werth, John L ^a   Moton, Allen E ^c   Gibson, Gordon ^d  

^a PFIZER INC   (United States)

^b GLAXOSMITHKLINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Clinical Study Centers LLC   (United States)

Author keywords

Insomnia; PD 0200390; Pharmacokinetics; Renal impairment; Safety

Indexed keywords

(1 AMINOMETHYL 3,4 DIMETHYLCYCLOPENTYL) ACETIC ACID; PD 0200390; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED CALCIUM CHANNEL ALPHA2 DELTA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HEADACHE; HUMAN; INSOMNIA; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; SCREENING; SINGLE DRUG DOSE; SOMNOLENCE; URINALYSIS;

ACETIC ACIDS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALCIUM CHANNELS; CYCLOPENTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KIDNEY DISEASES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; REFERENCE VALUES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SLEEP INITIATION AND MAINTENANCE DISORDERS; YOUNG ADULT;

EID: 68449093205     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03444.x     Document Type: Article

References (15)

1. Zammit GK. The prevalence, morbidities, and treatments of insomnia. CNS Neurol Disord Drug Targets 2007 6 : 3 16.
2. Ohayon MM, Caulet M, Priest RG, Guilleminault C. DSM-IV and ICSD-90 insomnia symptoms and sleep dissatisfaction. Br J Psychiatry 1997 171 : 382 8.
3. Morphy H, Dunn KM, Lewis M, Boardman HF, Croft PR. Epidemiology of insomnia: a longitudinal study in a UK population. Sleep 2007 30 : 274 80.
4. Simon GE, VonKorff M. Prevalence, burden and treatment of insomnia in primary care. Am J Psychiatry 1997 154 : 1417 23.
5. Léger D, Guilleminault C, Bader G, Lévy E, Paillard M. Medical and socio-professional impact of insomnia. Sleep 2002 25 : 625 9.
6. 2+ channel α2δ ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007 28 : 75 82.
7. Donevan S, Li Z, Serpa K, Meltzer L, Taylor C, Thorpe A. PD 0200390, a novel α2δ ligand, enhances slow wave sleep [abstract Biol Psychiatry 2008 63 (Suppl. 1 s102. Abstract no. 310.
8. Corrigan B, Werth J, Bramson C, Alvey C, Abel R, Feltner D, Ouellet D. Pharmacokinetics and pharmacodynamics of PD 0200390 following single-dose administration to healthy volunteers. Clin Pharmacol Ther 2008 83 (Suppl 1 S29. Abstract no. PI-69.
9. Corrigan B, Werth J, Moton A, Alvey C, Feltner D, Ouellet D. Pharmacokinetics of PD 0200390 following multiple dose administration to healthy volunteers. Clin Pharmacol Ther 2008 83 (Suppl 1 S30. Abstract no. PI-71.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
11. Pfizer Inc. Lyrica® (pregabalin) prescribing information. June 2007.
12. Fillastre JP, Geffroy-Josse S, Etienne I, Dhib M, Rosenzweig P, Danjou P, Dubruc C, Bianchetti G. Pharmacokinetics and pharmacodynamics of zolpidem following repeated doses in hemodialyzed uraemic patients. Fundam Clin Pharmacol 1993 7 : 1 9.
13. Halas CJ. Eszopiclone. Am J Health Syst Pharm 2006 63 : 41 8.
14. Sanofi-aventis. Ambien® (zolpidem) prescribing information. March 2007.
15. Sepracor Inc. Lunesta® (eszopiclone) prescribing information. December 2004.